Renaissance Technologies LLC Sells 132,797 Shares of Core Laboratories Inc. $CLB

Renaissance Technologies LLC trimmed its holdings in Core Laboratories Inc. (NYSE:CLB) by 72.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 50,603 shares of the oil and gas company’s stock after selling 132,797 shares during the period. Renaissance Technologies LLC owned 0.11% of Core Laboratories worth $850,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Core Laboratories by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,893 shares of the oil and gas company’s stock worth $418,000 after acquiring an additional 1,170 shares during the last quarter. American Century Companies Inc. lifted its holdings in Core Laboratories by 14.3% during the 2nd quarter. American Century Companies Inc. now owns 133,033 shares of the oil and gas company’s stock valued at $1,533,000 after purchasing an additional 16,677 shares during the last quarter. Quantbot Technologies LP lifted its holdings in Core Laboratories by 343.7% during the 2nd quarter. Quantbot Technologies LP now owns 17,520 shares of the oil and gas company’s stock valued at $202,000 after purchasing an additional 13,571 shares during the last quarter. Sei Investments Co. bought a new position in Core Laboratories during the second quarter worth $231,000. Finally, The Manufacturers Life Insurance Company boosted its position in Core Laboratories by 6.2% during the second quarter. The Manufacturers Life Insurance Company now owns 17,932 shares of the oil and gas company’s stock worth $207,000 after purchasing an additional 1,040 shares during the period. 97.81% of the stock is currently owned by institutional investors.

Insider Activity

In other Core Laboratories news, CEO Lawrence Bruno purchased 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were acquired at an average cost of $10.78 per share, for a total transaction of $53,900.00. Following the completion of the purchase, the chief executive officer owned 262,438 shares of the company’s stock, valued at approximately $2,829,081.64. The trade was a 1.94% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.26% of the company’s stock.

Core Laboratories Price Performance

Shares of NYSE CLB opened at $12.48 on Friday. The firm has a market cap of $572.54 million, a P/E ratio of 22.28, a price-to-earnings-growth ratio of 3.00 and a beta of 1.03. The business’s 50 day moving average is $11.60 and its 200-day moving average is $14.70. The company has a current ratio of 2.12, a quick ratio of 1.55 and a debt-to-equity ratio of 0.41. Core Laboratories Inc. has a 1-year low of $9.79 and a 1-year high of $20.36.

Core Laboratories (NYSE:CLB) last released its quarterly earnings results on Wednesday, July 29th. The oil and gas company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. Core Laboratories had a return on equity of 10.03% and a net margin of 5.10%.The business had revenue of $124.61 million during the quarter, compared to the consensus estimate of $126.26 million. During the same period in the previous year, the company posted $0.19 EPS. The firm’s quarterly revenue was down 4.3% on a year-over-year basis. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. Equities research analysts predict that Core Laboratories Inc. will post 0.53 earnings per share for the current year.

Core Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Monday, August 10th will be given a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, August 10th. Core Laboratories’s payout ratio is presently 7.14%.

Analyst Ratings Changes

Several brokerages have recently weighed in on CLB. Johnson Rice raised shares of Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a research report on Thursday. Weiss Ratings raised shares of Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, August 3rd. Finally, Wall Street Zen raised shares of Core Laboratories from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Core Laboratories Company Profile

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.